The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH 2017 | The future of AML and MDS diagnosis and treatment
There is currently a conundrum regarding the differentiation of acute myeloid leukemia and myelodysplastic syndromes. In this interview, Stéphane de Botton, MD, PhD of the Gustave Roussy Institute, Villejuif, France, speaking at the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Haematology (ESH), suggests diagnosing patients based on their genotype. He also stresses the significance of new and existing treatments, including chemotherapy, broad spectrum agents and immunotherapies.
